{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:02:17Z","timestamp":1790791337621,"version":"4.1.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K76AG064428"],"award-info":[{"award-number":["K76AG064428"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG077092"],"award-info":[{"award-number":["R21AG077092"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG088522"],"award-info":[{"award-number":["R01AG088522"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40266-024-01165-2","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T09:35:55Z","timestamp":1737192955000},"page":"95-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults"],"prefix":"10.1007","volume":"42","author":[{"given":"Ashkan","family":"Hashemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ji","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-3737","authenticated-orcid":false,"given":"Parag","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"3","key":"1165_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, B\u00f6hm M, Butler J, et al. Universal definition, and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society, and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail. 2021;23(3):352\u201380. https:\/\/doi.org\/10.1002\/ejhf.2115.","journal-title":"Eur J Heart Fail"},{"key":"1165_CR2","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","volume":"50","author":"GC Fonarow","year":"2007","unstructured":"Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol. 2007;50:768\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81:1810\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR4","first-page":"124","volume":"24","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;24:124.","journal-title":"Circ Res"},{"issue":"10","key":"1165_CR5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","volume":"29","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, Fonarow GC, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412\u201351. https:\/\/doi.org\/10.1016\/j.cardfail.2023.07.006.","journal-title":"J Card Fail"},{"key":"1165_CR6","first-page":"5","volume":"25","author":"R Samson","year":"2016","unstructured":"Samson R, Jaiswal A, Ennezat PV, Cassidy M, Jemtel THL. Clinical phenotypes in heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;25:5.","journal-title":"J Am Heart Assoc"},{"key":"1165_CR7","first-page":"145","volume":"2022","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;2022:145.","journal-title":"Circulation"},{"key":"1165_CR8","first-page":"81","volume":"9","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on management of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2023;9:81.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2022.100070","volume":"1","author":"P Goyal","year":"2022","unstructured":"Goyal P, Kwak MJ, Al Malouf C, et al. Geriatric cardiology: coming of age. JACC Adv. 2022;1: 100070.","journal-title":"JACC Adv."},{"key":"1165_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","volume":"171","author":"A Cherubini","year":"2011","unstructured":"Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171:550\u20136.","journal-title":"Arch Intern Med"},{"key":"1165_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137\u201355.","journal-title":"Eur J Heart Fail"},{"key":"1165_CR12","first-page":"339","volume":"6","author":"DC Brater","year":"1998","unstructured":"Brater DC. Diuretic therapy. N Engl J Med. 1998;6:339.","journal-title":"N Engl J Med"},{"key":"1165_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11897-024-00643-3","volume":"21","author":"JJ Cuthbert","year":"2024","unstructured":"Cuthbert JJ, Clark AL. Diuretic treatment in patients with heart failure: current evidence and future directions\u2014part I: loop diuretics. Curr Heart Fail Rep. 2024;21:101\u201314.","journal-title":"Curr Heart Fail Rep"},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1185\/03007997609111998","volume":"4","author":"C Kourouklis","year":"1976","unstructured":"Kourouklis C, Christensen O, Augoustakis D. Bumetanide in congestive heart failure. Curr Med Res Opin. 1976;4:422\u201331.","journal-title":"Curr Med Res Opin"},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/clpt.1986.228","volume":"40","author":"LG Sherman","year":"1986","unstructured":"Sherman LG, Liang C-S, Baumgardner S, Charuzi Y, Chardo F, Kim CS. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986;40:587\u201394.","journal-title":"Clin Pharmacol Ther"},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/BF01857763","volume":"4","author":"W Haerer","year":"1990","unstructured":"Haerer W, Bauer U, Sultan N, et al. Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure\u2014a placebo-controlled trial. Cardiovasc Drugs Ther. 1990;4:515\u201321.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-019-1194-9","volume":"21","author":"CC Leung","year":"2019","unstructured":"Leung CC. Current role of the CardioMEMS device for management of patients with heart failure. Curr Cardiol Rep. 2019;21:98.","journal-title":"Curr Cardiol Rep"},{"issue":"9766","key":"1165_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet. 2011;377(9766):658\u201366.","journal-title":"Lancet"},{"key":"1165_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2215\/CJN.09630818","volume":"14","author":"DH Ellison","year":"2019","unstructured":"Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol. 2019;14:1248\u201357.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1165_CR20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","volume":"75","author":"GM Felker","year":"2020","unstructured":"Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(10):1178\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.059.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","volume":"329","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure. JAMA. 2023;329:214.","journal-title":"JAMA"},{"key":"1165_CR22","doi-asserted-by":"crossref","unstructured":"Miller WL. Fluid volume homeostasis in heart failure: a tale of 2 circulations. J Am Heart Assoc. 2022;11(18):e026668","DOI":"10.1161\/JAHA.122.026668"},{"key":"1165_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ahj.2014.08.008","volume":"168","author":"SN Levin","year":"2014","unstructured":"Levin SN, Hajduk AM, McManus DD, et al. Cognitive status in patients hospitalized with acute decompensated heart failure. Am Heart J. 2014;168:917\u201323.","journal-title":"Am Heart J"},{"issue":"20","key":"1165_CR24","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964\u201375.","journal-title":"N Engl J Med"},{"key":"1165_CR25","doi-asserted-by":"crossref","unstructured":"Denfeld QE, Turrise S, Maclaughlin EJ, et al. Preventing and managing falls in adults with cardiovascular disease: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2022;15(6):e000108.","DOI":"10.1161\/HCQ.0000000000000108"},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/ejhf.811","volume":"19","author":"D Montero","year":"2017","unstructured":"Montero D, Flammer AJ. Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy? Eur J Heart Fail. 2017;19:971\u20133.","journal-title":"Eur J Heart Fail"},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.15420\/ecr.2015.10.01.42","volume":"10","author":"G Casu","year":"2015","unstructured":"Casu G, Merella P. Diuretic therapy in heart failure\u2014current approaches. Eur Cardiol Rev. 2015;10:42.","journal-title":"Eur Cardiol Rev."},{"key":"1165_CR28","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","volume":"75","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart failure. J Am Coll Cardiol. 2020;75:2836\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. JAMA. 2013;309:781.","journal-title":"JAMA"},{"key":"1165_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"1165_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34\u201342.","journal-title":"Circulation"},{"key":"1165_CR32","unstructured":"Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction, SPIRRIT-HFPEF. Uppsala University."},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jchf.2019.08.019","volume":"7","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, Claggett B, Vaduganathan M, et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC Heart Fail. 2019;7:1022\u20138.","journal-title":"JACC Heart Fail."},{"key":"1165_CR34","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460\u201370.","journal-title":"Circulation"},{"key":"1165_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","volume":"75","author":"CS Wilcox","year":"2020","unstructured":"Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension. 2020;75:894\u2013901.","journal-title":"Hypertension"},{"key":"1165_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:10.","journal-title":"Diabetologia"},{"key":"1165_CR37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med"},{"issue":"Suppl","key":"1165_CR38","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.cjca.2017.07.330","volume":"33","author":"S Kang","year":"2017","unstructured":"Kang S, Verma S, Teng G, et al. Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG outcome. Can J Cardiol. 2017;33(Suppl):S169.","journal-title":"Can J Cardiol"},{"key":"1165_CR39","doi-asserted-by":"crossref","unstructured":"Zhang Q, Deng Z, Li T, Chen K, Zeng Z. SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis. Front Cardiovasc Med. 2024;10:1280547.","DOI":"10.3389\/fcvm.2023.1280547"},{"key":"1165_CR40","doi-asserted-by":"crossref","unstructured":"Pahud De Mortanges A, Salvador D Jr, Laimer M, Muka T, Wilhelm M, Bano A. The role of SGLT2 inhibitors in atherosclerosis: a narrative mini-review. Front Pharmacol. 2021;12:751214.","DOI":"10.3389\/fphar.2021.751214"},{"key":"1165_CR41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398:262\u201376.","journal-title":"Lancet"},{"key":"1165_CR42","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.metabol.2012.05.014","volume":"61","author":"G Ndrepepa","year":"2012","unstructured":"Ndrepepa G, Braun S, King L, et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism. 2012;61:1780\u20136.","journal-title":"Metabolism"},{"key":"1165_CR43","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398.","journal-title":"N Engl J Med"},{"key":"1165_CR44","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1165_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117\u201328.","journal-title":"N Engl J Med"},{"key":"1165_CR46","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954\u201360.","journal-title":"Nat Med"},{"key":"1165_CR47","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","volume":"146","author":"JH Butt","year":"2022","unstructured":"Butt JH, Jhund PS, Belohl\u00e1vek J, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146:1210\u201324.","journal-title":"Circulation"},{"key":"1165_CR48","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jchf.2023.05.014","volume":"11","author":"A Peikert","year":"2023","unstructured":"Peikert A, Goyal P, Vaduganathan M, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status. JACC Heart Fail. 2023;11:1380\u201393.","journal-title":"JACC Heart Fail."},{"key":"1165_CR49","doi-asserted-by":"crossref","unstructured":"Goldman A, Fishman B, Twig G, et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265\u200975 years): a retrospective, pharmacovigilance study. Cardiovasc Diabetol. 2023;22:16.","DOI":"10.1186\/s12933-023-01743-5"},{"key":"1165_CR50","doi-asserted-by":"crossref","unstructured":"Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022;51:afac201.","DOI":"10.1093\/ageing\/afac201"},{"key":"1165_CR51","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","volume":"124","author":"JB McGill","year":"2019","unstructured":"McGill JB, Subramanian S. Safety of sodium-glucose co-transporter-2 inhibitors. Am J Cardiol. 2019;124:S45\u201352.","journal-title":"Am J Cardiol"},{"key":"1165_CR52","doi-asserted-by":"publisher","first-page":"147916412095362","DOI":"10.1177\/1479164120953625","volume":"17","author":"X Rong","year":"2020","unstructured":"Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diabetes Vasc Dis Res. 2020;17:147916412095362.","journal-title":"Diabetes Vasc Dis Res."},{"key":"1165_CR53","doi-asserted-by":"publisher","first-page":"e001856","DOI":"10.1136\/bmjdrc-2020-001856","volume":"8","author":"T Horii","year":"2020","unstructured":"Horii T, Oikawa Y, Kunisada N, Shimada A, Atsuda K. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study. BMJ Open Diabetes Res Care. 2020;8:e001856.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1165_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","volume":"63","author":"L Barski","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9\u201314.","journal-title":"Eur J Intern Med"},{"key":"1165_CR55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.HYP.0000168053.34306.d4","volume":"46","author":"DA Kass","year":"2005","unstructured":"Kass DA. Ventricular arterial stiffening. Hypertension. 2005;46:185\u201393.","journal-title":"Hypertension"},{"key":"1165_CR56","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension. J Am Coll Cardiol. 2018;71:1474\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR57","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ejhf.1436","volume":"21","author":"I Ikonomidis","year":"2019","unstructured":"Ikonomidis I, Aboyans V, Blacher J, et al. The role of ventricular\u2013arterial coupling in cardiac disease and heart failure: assessment, clinical implications, and therapeutic interventions. Eur J Heart Fail. 2019;21:402\u201324.","journal-title":"Eur J Heart Fail"},{"key":"1165_CR58","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fphys.2012.00090","volume":"3","author":"PD Chantler","year":"2012","unstructured":"Chantler PD, Lakatta EG. Arterial\u2013ventricular coupling with aging and disease. Front Physiol. 2012;3:90.","journal-title":"Front Physiol"},{"key":"1165_CR59","first-page":"937","volume":"3","author":"RA Hammoud","year":"2007","unstructured":"Hammoud RA, Vaccari CS, Nagamia SH, Khan BV. Regulation of the renin\u2013angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag. 2007;3:937\u201345.","journal-title":"Vasc Health Risk Manag."},{"key":"1165_CR60","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1161\/01.CIR.102.2.253","volume":"102","author":"T Tamura","year":"2000","unstructured":"Tamura T, Said S, Harris J, Lu W, Gerdes AM. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation. 2000;102:253\u20139.","journal-title":"Circulation"},{"key":"1165_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2020-7-3","volume":"9","author":"N Singhania","year":"2020","unstructured":"Singhania N, Bansal S, Mohandas S, Nimmatoori DP, Ejaz AA, Singhania G. Role of renin\u2013angiotensin\u2013aldosterone system inhibitors in heart failure and chronic kidney disease. Drugs Context. 2020;9:1\u20139.","journal-title":"Drugs Context."},{"key":"1165_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","volume":"8","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Neprilysin inhibitors in heart failure. JACC Basic Transl Sci. 2023;8:88\u2013105.","journal-title":"JACC Basic Transl Sci."},{"key":"1165_CR63","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"1165_CR64","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes, and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230\u20139.","journal-title":"Eur J Heart Fail"},{"key":"1165_CR65","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","journal-title":"N Engl J Med"},{"key":"1165_CR66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","volume":"4","author":"IS Anand","year":"2011","unstructured":"Anand IS, Rector TS, Cleland JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011;4:569\u201377.","journal-title":"Circ Heart Fail"},{"key":"1165_CR67","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"1165_CR68","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352\u201361.","journal-title":"Circulation"},{"key":"1165_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","volume":"75","author":"SE Kjeldsen","year":"2020","unstructured":"Kjeldsen SE, Von Lueder TG, Smiseth OA, et al. Medical therapies for heart failure with preserved ejection fraction. Hypertension. 2020;75:23\u201332.","journal-title":"Hypertension"},{"key":"1165_CR70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/life11010060","volume":"11","author":"C Izzo","year":"2021","unstructured":"Izzo C, Vitillo P, Di Pietro P, et al. The role of oxidative stress in cardiovascular aging and cardiovascular diseases. Life. 2021;11:60.","journal-title":"Life"},{"key":"1165_CR71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","volume":"72","author":"G Jia","year":"2018","unstructured":"Jia G, Aroor AR, Hill MA, Sowers JR. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72:537\u201348.","journal-title":"Hypertension"},{"key":"1165_CR72","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, et al. Renin\u2013angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021\u201332.","journal-title":"N Engl J Med"},{"issue":"22","key":"1165_CR73","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316.","journal-title":"N Engl J Med"},{"key":"1165_CR74","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","volume":"3","author":"A Tsimploulis","year":"2018","unstructured":"Tsimploulis A, Lam PH, Arundel C, et al. Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2018;3:288.","journal-title":"JAMA Cardiol."},{"key":"1165_CR75","doi-asserted-by":"crossref","unstructured":"Faselis C, Lam PH, Zile MR, Bhyan P, Tsimploulis A, Arundel C, et al. Systolic blood pressure and outcomes in older patients with HFpEF and hypertension. Am J Med. 2021;134(4):e252\u2013e263.","DOI":"10.1016\/j.amjmed.2020.08.030"},{"key":"1165_CR76","doi-asserted-by":"crossref","unstructured":"Hassan M. Towards tailoring blood pressure control in HFpEF: lessons from OPTIMIZE-HF. Glob Cardiol Sci Pract. 2019;2019:3.","DOI":"10.21542\/gcsp.2019.3"},{"key":"1165_CR77","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","volume":"75","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Claggett BL, B\u00f6hm M, et al. Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan. J Am Coll Cardiol. 2020;75:1644\u201356.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"1165_CR78","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1161\/CIRCULATIONAHA.117.028307","volume":"135","author":"N Sattar","year":"2017","unstructured":"Sattar N, Preiss D. Reverse causality in cardiovascular epidemiological research: more common than imagined? Circulation. 2017;135(24):2369\u201372.","journal-title":"Circulation"},{"key":"1165_CR79","doi-asserted-by":"crossref","unstructured":"Vardeny O, Claggett B, Kachadourian J, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril. Circ Heart Fail. 2018;11:e004745.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745"},{"key":"1165_CR80","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.CIR.101.5.558","volume":"101","author":"MR Bristow","year":"2000","unstructured":"Bristow MR. \u03b2-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558\u201369.","journal-title":"Circulation"},{"key":"1165_CR81","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","volume":"350","author":"MR Zile","year":"2004","unstructured":"Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure\u2014abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953\u20139.","journal-title":"N Engl J Med"},{"key":"1165_CR82","doi-asserted-by":"crossref","unstructured":"Meyer M, Lewinter MM. Heart rate and heart failure with preserved ejection fraction. Circ Heart Fail. 2019;12:e006213.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213"},{"key":"1165_CR83","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ejhf.2146","volume":"23","author":"E Wolsk","year":"2021","unstructured":"Wolsk E, Kaye DM, Komtebedde J, et al. Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2021;23:754\u201364.","journal-title":"Eur J Heart Fail"},{"key":"1165_CR84","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/ehf2.12281","volume":"5","author":"E Dom\u00ednguez","year":"2018","unstructured":"Dom\u00ednguez E, Palau P, N\u00fa\u00f1ez E, et al. Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction. ESC Heart Fail. 2018;5:579\u201385.","journal-title":"ESC Heart Fail."},{"key":"1165_CR85","doi-asserted-by":"crossref","unstructured":"Zweerink A, Van Der Lingen A-LCJ, Handoko ML, Van Rossum AC, Allaart CP. Chronotropic incompetence in chronic heart failure. Circ Heart Fail. 2018;11:e004969.","DOI":"10.1161\/CIRCHEARTFAILURE.118.004969"},{"key":"1165_CR86","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507\u201315.","journal-title":"Nat Rev Cardiol"},{"key":"1165_CR87","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810\u201352.","journal-title":"Circulation"},{"key":"1165_CR88","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","volume":"15","author":"K Yamamoto","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M, Investigators JD. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013;15:110\u20138.","journal-title":"Eur J Heart Fail"},{"key":"1165_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26\u201335.","journal-title":"Eur Heart J"},{"key":"1165_CR90","doi-asserted-by":"publisher","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","volume":"2","author":"DN Silverman","year":"2019","unstructured":"Silverman DN, Plante TB, Infeld M, et al. Association of beta-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Netw Open. 2019;2:e1916598.","journal-title":"JAMA Netw Open"},{"key":"1165_CR91","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","volume":"78","author":"P Palau","year":"2021","unstructured":"Palau P, Seller J, Dominguez E, et al. Effect of beta-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol. 2021;78:2042\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR92","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","volume":"132","author":"N Pal","year":"2015","unstructured":"Pal N, Sivaswamy N, Mahmod M, et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation. 2015;132:1719\u201325.","journal-title":"Circulation"},{"key":"1165_CR93","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/gerona\/gly191","volume":"74","author":"AR Zullo","year":"2019","unstructured":"Zullo AR, Olean M, Berry SD, Lee Y, Tjia J, Steinman MA. Patient-important adverse events of \u03b2-blockers in frail older adults after acute myocardial infarction. J Gerontol A Biol Sci Med Sci. 2019;74:1277\u201381.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1165_CR94","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","volume":"27","author":"EG Knox","year":"2022","unstructured":"Knox EG, Aburto MR, Clarke G, Cryan JF, O\u2019Driscoll CM. The blood\u2013brain barrier in aging and neurodegeneration. Mol Psychiatry. 2022;27:2659\u201373.","journal-title":"Mol Psychiatry"},{"key":"1165_CR95","doi-asserted-by":"crossref","unstructured":"Elkammash A, Tam SSC, Yogarajah G, You J. Management of heart failure with preserved ejection fraction in elderly patients: effectiveness and safety. Cureus. 2023;15(2):e35030.","DOI":"10.7759\/cureus.35030"},{"key":"1165_CR96","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/CIRCULATIONAHA.110.940577","volume":"123","author":"PH Brubaker","year":"2011","unstructured":"Brubaker PH, Kitzman DW. Chronotropic incompetence. Circulation. 2011;123:1010\u201320.","journal-title":"Circulation"},{"key":"1165_CR97","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/jgs.15977","volume":"67","author":"B Yum","year":"2019","unstructured":"Yum B, Archambault A, Levitan EB, et al. Indications for beta-blocker prescriptions in heart failure with preserved ejection fraction. J Am Geriatr Soc. 2019;67:1461\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"1165_CR98","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1532-5415.2011.03772.x","volume":"60","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60:34\u201341.","journal-title":"J Am Geriatr Soc"},{"key":"1165_CR99","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamainternmed.2016.7701","volume":"177","author":"MA Steinman","year":"2017","unstructured":"Steinman MA, Zullo AR, Lee Y, et al. Association of beta-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction. JAMA Intern Med. 2017;177:254\u201362.","journal-title":"JAMA Intern Med"},{"key":"1165_CR100","doi-asserted-by":"crossref","unstructured":"Frishman WH. Beta-adrenergic receptor blockers: adverse effects and drug interactions. Hypertension. 1988;11:1121-1129.","DOI":"10.1161\/01.HYP.11.3_Pt_2.II21"},{"key":"1165_CR101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/01.CRD.0000053453.89776.2D","volume":"11","author":"S Keller","year":"2003","unstructured":"Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev. 2003;11:73\u201393.","journal-title":"Cardiol Rev"},{"key":"1165_CR102","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1161\/HYPERTENSIONAHA.120.16590","volume":"77","author":"TG Riemer","year":"2021","unstructured":"Riemer TG, Villagomez Fuentes LE, Algharably EAE, et al. Do beta-blockers cause depression? Systematic review and meta-analysis of psychiatric adverse events during beta-blocker therapy. Hypertension. 2021;77:1539\u201348.","journal-title":"Hypertension"},{"key":"1165_CR103","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740\u201356.","journal-title":"Cell Metab"},{"key":"1165_CR104","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction. JAMA. 2023;329:827.","journal-title":"JAMA"},{"key":"1165_CR105","doi-asserted-by":"crossref","unstructured":"GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen\nRM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N. Glycemia reduction in type 2 diabetes\u2014glycemic outcomes. N Engl J Med. 2022; 387:1063-1074.","DOI":"10.1056\/NEJMoa2200433"},{"key":"1165_CR106","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4239\/wjd.v15.i5.818","volume":"15","author":"L Nesti","year":"2024","unstructured":"Nesti L, Trico D. Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: myth or truth? World J Diabetes. 2024;15:818\u201322.","journal-title":"World J Diabetes"},{"key":"1165_CR107","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijcard.2022.03.032","volume":"357","author":"A Avogaro","year":"2022","unstructured":"Avogaro A, Azzolina D, Gregori D, De Kreutzenberg S, Fadini GP, Mannucci E. The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide: a scoping review and meta-analysis. Int J Cardiol. 2022;357:123\u20137.","journal-title":"Int J Cardiol"},{"key":"1165_CR108","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u201384.","journal-title":"N Engl J Med"},{"key":"1165_CR109","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Butler J, Borlaug BA, et al. Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction. J Am Coll Cardiol. 2024;84:773\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR110","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","volume":"84","author":"M Schou","year":"2024","unstructured":"Schou M, Petrie MC, Borlaug BA, et al. Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction. J Am Coll Cardiol. 2024;84:247\u201357.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR111","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, et al. Effects of once weekly semaglutide on appetite, energy intake, control of eating, food preference, and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"1165_CR112","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1111\/jgs.18590","volume":"71","author":"O Zainul","year":"2023","unstructured":"Zainul O, Perry D, Pan M, et al. Malnutrition in heart failure with preserved ejection fraction. J Am Geriatr Soc. 2023;71:3367\u201375.","journal-title":"J Am Geriatr Soc"},{"key":"1165_CR113","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","volume":"34","author":"JA Sargeant","year":"2019","unstructured":"Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab (Seoul). 2019;34:247\u201362.","journal-title":"Endocrinol Metab (Seoul)."},{"key":"1165_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2019.03.006","volume":"45","author":"S Carbone","year":"2020","unstructured":"Carbone S, Billingsley HE, Rodriguez-Miguelez P, et al. Lean mass abnormalities in heart failure: the role of sarcopenia, sarcopenic obesity, and cachexia. Curr Probl Cardiol. 2020;45: 100417.","journal-title":"Curr Probl Cardiol"},{"key":"1165_CR115","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.jacc.2023.09.812","volume":"82","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan M, Ostrominski JW. Glucagon-like peptide-1 receptor agonists in heart failure: STEPPing across the ejection fraction divide. Am Coll Cardiol Found. 2023;82:2097\u2013100.","journal-title":"Am Coll Cardiol Found."},{"key":"1165_CR116","doi-asserted-by":"crossref","unstructured":"Kitzman DW, Lewis GD, Pandey A, et al. A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: rationale and design of the Phase 2a HuMAIN trial. Eur J Heart Fail. 2024;26(9):2013-24.","DOI":"10.1002\/ejhf.3305"},{"key":"1165_CR117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab."},{"key":"1165_CR118","volume-title":"Mitochondrial uncoupler HU6 reduces hepatic oxidative stress in the DIAMOND mouse model thus abrogating NASH development","author":"F Portell","year":"2018","unstructured":"Portell F, Eaton S, Dennis J, et al. Mitochondrial uncoupler HU6 reduces hepatic oxidative stress in the DIAMOND mouse model thus abrogating NASH development. Paris: EASL: European Association for the Study of the Liver; 2018."},{"key":"1165_CR119","doi-asserted-by":"crossref","unstructured":"Andre P, Joshi SR, Briscoe SD, Alexander MJ, Li G, Kumar R. Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-\u03b2 superfamily signaling. Front Med. 2022;8:814222.","DOI":"10.3389\/fmed.2021.814222"},{"key":"1165_CR120","doi-asserted-by":"crossref","unstructured":"Joshi SR, Liu J, Bloom T, et al. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Sci Rep. 2022;12:7435.","DOI":"10.1038\/s41598-022-11435-x"},{"key":"1165_CR121","doi-asserted-by":"crossref","unstructured":"Yung LM, Yang P, Joshi S, et al. ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med. 2020;12:eaaz5660.","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"1165_CR122","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, \u00c9des I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications. Int J Cardiol. 2012;159:82\u20137.","journal-title":"Int J Cardiol"},{"key":"1165_CR123","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","volume":"30","author":"M Petrie","year":"2024","unstructured":"Petrie M, Borlaug B, Buchholtz K, et al. HERMES: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. J Card Fail. 2024;30:126.","journal-title":"J Card Fail"},{"key":"1165_CR124","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cardfail.2023.04.003","volume":"30","author":"CSP Lam","year":"2024","unstructured":"Lam CSP, Lund LH, Shah SJ, et al. Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results. J Card Fail. 2024;30:104\u201310.","journal-title":"J Card Fail"},{"key":"1165_CR125","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369.","journal-title":"Lancet"},{"key":"1165_CR126","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.3810","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, Rigolli M, Javidialsaadi A, Patel RB, Khadra S, Goyal P, Little S, Wever-Pinzon O, Owens AT, Skali H, Arora P, Solomon SD. Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. JAMA Cardiol. 2024. https:\/\/doi.org\/10.1001\/jamacardio.2024.3810. (Epub ahead of print, PMID: 39347697).","journal-title":"JAMA Cardiol."},{"key":"1165_CR127","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"1165_CR128","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","volume":"373","author":"MM Redfield","year":"2015","unstructured":"Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373:2314\u201324.","journal-title":"N Engl J Med"},{"key":"1165_CR129","doi-asserted-by":"crossref","unstructured":"Unlu O, Levitan EB, Reshetnyak E, et al. Polypharmacy in older adults hospitalized for heart failure. Circ Heart Fail. 2020;13:e0006977.","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977"},{"key":"1165_CR130","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","volume":"393","author":"BP Halliday","year":"2019","unstructured":"Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomized trial. Lancet. 2019;393:61\u201373.","journal-title":"Lancet"},{"key":"1165_CR131","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cardfail.2024.01.005","volume":"30","author":"E Driggin","year":"2024","unstructured":"Driggin E, Goyal P. Malnutrition and sarcopenia as reasons for caution with GLP-1 receptor agonist use in HFpEF. J Card Fail. 2024;30:610\u20132.","journal-title":"J Card Fail"},{"key":"1165_CR132","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1161\/CIRCULATIONAHA.123.064071","volume":"147","author":"AA Damluji","year":"2023","unstructured":"Damluji AA, Alfaraidhy M, Alhajri N, et al. Sarcopenia and cardiovascular diseases. Circulation. 2023;147:1534\u201353.","journal-title":"Circulation"},{"key":"1165_CR133","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.jacc.2018.02.059","volume":"71","author":"EZ Gorodeski","year":"2018","unstructured":"Gorodeski EZ, Goyal P, Hummel SL, et al. Domain management approach to heart failure in the geriatric patient. J Am Coll Cardiol. 2018;71:1921\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"1165_CR134","unstructured":"Institute for Healthcare Improvement. Age-friendly health systems. 2024. https:\/\/www.ihi.org\/networks\/initiatives\/age-friendly-health-systems."},{"issue":"2","key":"1165_CR135","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cardfail.2020.09.473","volume":"27","author":"P Goyal","year":"2021","unstructured":"Goyal P, Unlu O, Kennel PJ, Schumacher RC, Gilstrap LG, Krishnaswami A, Allen LA, Maurer MS, Rich MW, Makam A. Inclusion of performance parameters and patient context in the clinical practice guidelines for heart failure. J Card Fail. 2021;27(2):190\u20137.","journal-title":"J Card Fail"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01165-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01165-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T22:47:07Z","timestamp":1738795627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01165-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01165-2","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"17 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Goyal is supported by National Institute on Aging Grants K76AG064428, R21AG077092, and R01AG088522. The National Institute on Aging did not have a role in the design, methods, subject recruitment, data collections, analysis, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Goyal was a member of the Junior Investigator Intensive Program of the US Deprescribing Research Network and is supported by a US Deprescribing Research Pilot Grant funded by the National Institute on Aging (R24AG064025). Dr. Goyal has received consulting fees from Agepha Pharma, Akros Pharma, Axon therapies, Bayer HealthCare Pharmaceuticals, and Sensorum Health. Dr. Min Ji Kwak receives consult fee from Novo Nordisk and Diabetes and Endocrine Plus Clinic. Dr. Ashkan Hashemi reports no conflicts. Dr. Parag Goyal is an Editorial Board member of Drugs and Aging. Dr. Parag Goyal was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing not applicable to this article as no datasets were generated for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed equally to the conceptualization, methodology, writing, and reviewing and editing of the manuscript. Dr. Goyal supervised the entire process as the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}